H.C. Wainwright raised the firm’s price target on Kyverna Therapeutics (KYTX) to $10 from $5 and keeps a Buy rating on the shares. The firm says the company’s key opinion leader event provided a key disclosure that all three compassionate-use myasthenia gravis patients treated with KYV-101 remain in drug-free, disease-free remission, with follow-up now at 24 months, 22 months, and 15 months, respectively. The data strengthens H.C. Wainwright’s conviction in KYV-101’s long-term prospects.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics’ KYV-101: A Promising Investment in Addressing Unmet Needs in SPS and gMG
- Kyverna Therapeutics to host KOL event on neuroimmunology CAR T franchise
- Kyverna Therapeutics initiated with an Outperform at William Blair
- Kyverna Therapeutics: Promising Potential in Immune Cell Therapies with KYV-101
- Kyverna Therapeutics: Promising Clinical Progress and Strategic Advancements Drive Buy Rating